India's First MRNA COVID-19 Vaccine Phase-I Clinical Trial Gets Nod

[email protected]21 Sep, 2021News

The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study. "Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted for the phase 2 and 3 studies by Gennova Biopharmaceuticals Limited, a Pune-based biotechnology company," the Ministry of Science and Technology said in a release on Tuesday.

Recent Profiles

Fuglsang Barrett

Fuglsang Barrett

View Profile

Rowe Martin

Rowe Martin

View Profile

Godwin Horton

Godwin Horton

View Profile

Win678

Win678

View Profile

Broe Rahbek

Broe Rahbek

View Profile

Frandsen Johnson

Frandsen Johnson

View Profile

Sears Richards

Sears Richards

View Profile

Reese Thisted

Reese Thisted

View Profile

Gallagher Kelleher

Gallagher Kelleher

View Profile

Reece Sharma

Reece Sharma

View Profile